Biotech entity

NHS England

organization

clinical-trial is the sole category represented across all 1 tracked stories. Puberty Blockers is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. We currently track 1 Biotech story that mention NHS England, all published on February 20, 2026.

Last mentioned: Jul 12, 2026

Entity pulse

Recent coverage · NHS England

1 story
7 avg impact
0% positive
100% negative

Coverage balance Negative coverage leads. Negative coverage exceeds positive coverage by 100 percentage points.

  • 100% negative

Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.

What the coverage shows about NHS England

clinical-trial is the sole category represented across all 1 tracked stories. Puberty Blockers is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. We currently track 1 Biotech story that mention NHS England, all published on February 20, 2026. Each carries 9 original sources on average.

Stories tracked
1
Sources per story
9

Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 9 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.

Coverage cohort

Appears alongside

Other entities that clear the same relevance threshold in stories also covering NHS England. Shared-story counts are live from our verified record — not editorial picks.

Timeline

  1. MHRA Intervention

    The UK medicines regulator issues a formal pause on the trial due to newly identified concerns.

  2. Clinical Trial Launch

    NHS England begins the formal clinical trial to gather data on the effects of puberty blockers.

  3. Cass Review Published

    Final report recommends that puberty blockers only be administered within a research framework.

Stories mentioning NHS England 1

Clinical Trials Negative

MHRA Halts UK Puberty Blocker Clinical Trial Amid Safety Concerns

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has suspended a pivotal clinical trial investigating the use of puberty blockers for children. The pause follows the emergence of new regulatory concerns, effectively halting the primary research pathway for gender-affirming care in the UK.

9 sources

NHS England is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.

See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.